(Bikker et al., 1998) Quantitative studies of how drugs modulate their targets have been instrumental However, several challenges have limited the use of mutagenesis in drug discovery. In summary, mutagenesis can be a critical tool in drug discovery, particularly for studying GPCRs. G-protein coupled receptors: models, mutagenesis, and drug design. Molecular determinants of ligand efficacy and potency in GPCR signaling.

GPCRs continue to be regarded as one of the most tractable classes of drug targets and are targeted by 30%–40% of current drugs (Hauser et al., 2017), with annual sales of GPCR-targeting drugs in 2018 accounting Despite this high number of GPCR targeted drugs, only a small portion (∼110) of the human GPCRome (consisting of approximately 850 GPCRs) has been successfully drugged, and obtaining highly potent and selective Read more at the source #DrGPCR #GPCR #IndustryNews

of novel drugs, optimize drug design processes, and enhance the understanding of GPCR biology. De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding Multi-target drug design: GPCRs are often involved in complex signaling networks. With the revolution of biased signalling of GPCRs comes the possibility of designing drugs that selectively the process, optimizing drug design, and improving success rates.

drugs in treating a range of health conditions, from cancer and genetic disorders to inflammation and to that star are Verily and Sosei Heptares, which have struck a research agreement to discover new GPCR targets that’ll fuel the development of potential drug candidates. drug discovery have clocked in at $1 billion—with Genentech—and, just last November, $2.6 billion in Read more at the source #DrGPCR #GPCR #IndustryNews

The Cell Surface Is Only Part of the Story For decades, GPCR pharmacology centered on events at the cell This framework shaped how assays were designed, how drug candidates were profiled, and how efficacy was Work on receptors such as GLP-1R and MC4R has demonstrated that internalized GPCRs can continue to signal BRET-based assays can quantify beta-arrestin recruitment and, depending on the assay design, distinguish Terry Kenakin’s session on measuring GPCR internalization walks through the assay logic, the mechanistic

2026 GPCR Pharmacology AMA: Receptor Theory, Biased Signaling & Assay Interpretation The first GPCR Pharmacology Kenakin will address receptor theory, assay interpretation, biased signaling, and practical drug discovery disciplined interpretation As the archive grows, it becomes a searchable extension of Terry’s teaching — designed as new videos are released: ▶️ https://www.youtube.com/@TerryPharmacologyCorner New White Paper on GPCR School of Medicine, has authored a new white paper in collaboration with Eurofins DiscoverX: Assess GPCR

structural biology and drug discovery at opioid and galanin receptors. Joseph Kim: Structural Biology and Drug Discovery at GPCRs Cryo-EM has transformed how we visualize receptor–ligand interactions — and with it, how we think about drug discovery at GPCRs. GPCR Dr. GPCR is the intelligence and community platform for GPCR scientists. Plus 6 industry updates and 1 new Masterclass recording now available — Purinergic GPCR Ligand Design

GPCRs pose a critical challenge in drug discovery: a vast therapeutic potential with many targets yet to be explored.  35% of FDA-approved drugs target GPCRs, showing their importance in numerous physiological However, over half of non-sensory GPCRs do not have drugs available in the clinic, opening the door to Thus, rational design using efficient synthetic strategies is needed to make these probes as specific Our scientific team can guide you choose or design the right fluorescent ligand for your research.  

But pharmacology introduces a sobering truth: A drug that cannot reach its target is not a drug. Chemists Make The Drugs Drug discovery is fundamentally a team sport . both disciplines collaborate effectively, pharmacology data becomes a roadmap that guides molecular design toward viable drug candidates. teams navigating development bottlenecks scientific leaders seeking clear pharmacological guidance GPCR

 sit at the core of drug discovery. Yet small design choices—often treated as technical details—quietly reshape the affinity you think you Design GPCR binding affinity experiments that tell the truth , ensuring affinity data support—rather in-depth lessons and 3 live AMAs  spanning binding, kinetics, efficacy, mechanism, and experimental design—built GPCR Premium Membership Gives You an Edge Premium Membership is designed for scientists and teams who

Broichhagen aka JB, the goal was bold and elegant: Create a photo-switchable ligand to remotely control GPCR They had a tool that did bind the GPCR… but not in the light-controlled way they wanted. For metabolic GPCRs (like GLP-1 and GIP receptors): Drug efficacy depends on which cells express the Clarify brain vs. peripheral contributions to metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic strategies It didn’t just solve a problem.

Approximately one-third of the drugs currently in clinical use are GPCR ligands. The efficiency, versatility, and convergence of our proprietary conjugation technology enabled the design Conclusions By applying our proprietary technology, we have designed and synthesized two optimal fluorescent Trends in GPCR Drug Discovery: New Agents, Targets and Indications. Nature Reviews Drug Discovery 2017 , 16 (12), 829–842. https://doi.org/10.1038/nrd.2017.178 . (2) Dumitru

of the prime targets for marketed drugs. While traditional drug discovery programs have focused on the development of ligands targeting the binding current strategies for the identification of allosteric sites as well as ligand-based and structure-based drug discovery and design." Read more at the source #DrGPCR #GPCR #IndustryNews

Introduction G protein-coupled receptors (GPCRs) remain one of the most important classes of drug targets fluorescent or luminescent calcium measurements depending on instrumentation preferences and assay design PathHunter® Assays and Calcium Signaling Although PathHunter assays are primarily designed to measure calcium mobilization one of the most commonly used functional readouts in drug discovery. biology and accelerate drug discovery programs.

After a brief pause over the holidays and last month, we’re back in full force—designed to help you make Targeted Drug Discovery Summit, Boston. fundamentals while keeping pace with modern GPCR research and drug discovery. GPCR Podcast—GPCR Assay Strategy, Bias, and Translational Drug Discovery In this episode of the Dr. GPCR Premium is designed for scientists and teams who can’t afford to chase every headline—or miss the

Kenakin’s latest   lecture delivers exclusive, real-world insight designed to equip you to move beyond surface-level affinity data and make faster, more confident decisions in your drug discovery pipeline In this session, you’ll gain: ✅ A practical framework for understanding when a drug’s rate of binding truly reflects equilibrium—and when it doesn’t This is practical kinetic expertise—crafted to help drug s Corner   ______ #DrugDiscovery #Pharmacology #DrugKinetics #PipelineEfficiency #PharmaInnovation #GPCR

Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery G-protein-coupled receptors GPCR dimers are therefore emerging drug targets in different therapeutic areas including depression, What is the potential of targeting GPCR dimer interface in drug discovery? GPCR drugs efficacy usually depends on a pathway (G protein or β-arrestin), whereas side effects are dimerization while accelerating drug discovery targeting GPCR dimers.

was a set of chemical probes that finally allowed researchers to visualize where receptors exist, how drugs Why GPCR Collaboration Is Essential for Modern Science Hodson makes the point bluntly: modern GPCR science Together, they push GPCR science faster. It will hinge on the teams who can map GPCR signaling with precision and design therapies that fit real pathways Creating chemical tools that finally show how drugs reach their targets These aren’t solo-lab

Selectivity is one of the most overused—and misunderstood—terms in drug discovery. Without full curves, you cannot separate drug properties from detection limitations. In a world of increasingly complex GPCR modulation, these distinctions are not academic. It is designed for: Pharmacologists sharpening foundational tools Discovery teams solving assay bottlenecks Leaders making mechanism-driven portfolio decisions GPCR innovation is accelerating.

October 2022 GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches This approach can expand the repertoire of adenosine receptor antagonists that can be designed based Read more at the source #DrGPCR #GPCR #IndustryNews

Nasdaq debutante Septerna swells its IPO to $331m Nxera Pharma and Antiverse Enter Collaboration To Design Therapeutics, Inc. has received Orphan Drug Designation (ODD) from the FDA for its hematopoietic stem Drugs like Ozempic will change the world GPCR Events, Meetings, and Webinars November 5 - 7, 2024 | 16th Forum Conference November 26 - 28, 2024 | GPCRs-Targeted Drug Discovery Summit Europe NEW December of Advanced Multimodal Approaches to GPCR Drug Discovery NEW March 12 - 14, 2025 | NextGen Biomed 2025

— a transformation that reshaped how scientists design experiments and interpret signaling. The field moved from single readouts to integrated signaling landscapes, accelerating drug discovery Today, success depends less on manual precision and more on experimental design, data interpretation, What started as hand-built assays on ice has become integrated platforms for drug discovery, systems GPCR Podcast 🔓 Get tools, deep dives, and exclusive insights with   Dr. GPCR Premium .

Notably, G-protein-coupled receptors (GPCRs), representing the biggest drug target, have been revealed Historically, drug discovery efforts targeting GPCRs focused on G-protein-dependent signaling pathways drug discovery (Eishingdrelo & Kongsamut, 2013). Minireview: targeting GPCR activated ERK pathways for drug discovery. Biased receptor signaling in drug discovery. Pharmacological Reviews, 71(2), 267-315.

Why this matters Receptor distribution shapes incretin hormone drug effects across islets and neural Sparked a Scientific Journey Molecular Creativity in Drug Discovery Why Dr. publications, events, insights, and opportunities designed to support your career, your lab, or your Aside from his vast experience in drug development, not to mention his extensive publication record, GPCR Team

Rather than carving out turf, they grew by designing around collective capacity . techniques, not just one pipeline Senior scientists embedded as “connectors” between programs This design It was designed. Weekly seminars were mandatory but lightweight, designed to connect  rather than perform. This ecosystem design blueprint applies to biotech teams and academic consortia alike.

Are you ready to truly understand how pharmacologists predict whole-body drug response from a single Probability Models   This is practical drug development expertise from Terry’s 40+ years of experience GPCR News.   Elevate your pharmacology expertise. Unlock "Pharmacologic Models" now

depression, schizophrenia and Parkinson’s disease. [1,2] Several dopamine ligands have been approved as drugs Altogether, these aspects hint that the linker design and strategy can provide options for the tuning Current Drug Treatments Targeting Dopamine D3 Receptor. Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y1 Receptor. J. An Order of Magnitude Faster DNA-PAINT Imaging by Optimized Sequence Design and Buffer Conditions.

April 29, and the GPCRs Drug Discovery Summit April 28-30. iPSC-Derived GPCR Models: Beyond HEK293 for producing a fundamentally different pharmacological pattern — with different consequences for assay design allosteric binding modes, and why establishing that distinction early carries immense practical value for drug GPCR at the GPCRs Targeted Drug Discovery Summit — Boston, April 28-30 The GPCRs Targeted Drug Discovery GPCR University Learner About Dr. GPCR Dr.

Eric Trinquet, a veteran innovator behind functional GPCR assays like HTRF and IP-One, believes rigid If you’re building tools or careers in GPCR science, this is your playbook. It began with an unmet need: how to track Gq-coupled GPCR activity without the mess of calcium flux or GPCR   Dr. GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr. GPCR Premium Ecosystem  for behind-the-scenes access to GPCR innovators, exclusive deep-dives, and practical

GPCR Ecosystem. A GPCR Internalization Tool Designed for Real Research Needs Built on more than two decade A GPCR Internalization Tool Designed for Real Research Needs s of GPCR assay innovation , pHSense™  was developed to overcome GPCR. GPCR Dr.